MedPath

Efficacy Testing of VeCollal Products

Not Applicable
Completed
Conditions
Skin Condition
Interventions
Dietary Supplement: VeCollal sachet
Dietary Supplement: Placebo sachet
Dietary Supplement: Collagen sachet
Registration Number
NCT05789368
Lead Sponsor
TCI Co., Ltd.
Brief Summary

To assess VeCollal formula on skin condition improvement

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Healthy adults aged above 20 years old
Exclusion Criteria
  • Subject who is not willing to participate in this study.
  • Patients with diseases of the skin, liver, kidney.
  • Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Received facial laser therapy, chemical peeling or UV overexposure (> 3 hr/week) in the past 4 weeks.
  • Constant drug use
  • Students who are currently taking courses taught by the principal investigator of this trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VeCollal sachetVeCollal sachetconsume 1 sachet per day
Placebo sachetPlacebo sachetconsume 1 sachet per day
Collagen sachetCollagen sachetconsume 1 sachet per day
Primary Outcome Measures
NameTimeMethod
The change of skin wrinklesChange from Baseline skin wrinkles at 8 weeks

VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units

The change of skin textureChange from Baseline skin texture at 8 weeks

VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

The change of skin collagen densityChange from Baseline skin collagen density at 8 weeks

DermaLab® Series SkinLab Combo was utilized to measure skin pores. Units: arbitrary units

The change of skin elasticityChange from Baseline skin elasticity at 8 weeks

SoftPlus was utilized to measure skin elasticity. Units: arbitrary units

Secondary Outcome Measures
NameTimeMethod
The change of skin L* valueChange from Baseline skin L* value at 8 weeks

Chroma Meter MM500 was utilized to measure skin L\* value. Units: arbitrary units, 0-100

The change of skin erythema indexChange from Baseline skin erythema index at 8 weeks

Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary units

The change of skin moistureChange from Baseline skin moisture index at 8 weeks

Corneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120

The change of skin melanin indexChange from Baseline skin melanin index at 8 weeks

Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary units

The change of transepidermal water loss (TEWL)Change from Baseline skin TEWL at 8 weeks

Tewameter® TM 300 was utilized to measure TEWL. Units: g/hm²

The change of skin poresChange from Baseline skin pores at 8 weeks

VISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units

Trial Locations

Locations (1)

Chia Nan University of Pharmacy & Science

🇨🇳

Tainan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath